Communication

Synthesis and Evaluation of Self-Assembling Properties of 3-(3,5-Difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium Iodides

Nadiia Pikun 1, Davis Lacis 1, Arkadij Sobolev 1, Martins Rucins 1, Mara Plotniece 2, Karlis Pajuste 1 and Aiva Plotniece 1,2,*

Abstract: A synthesis of 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodides with ethyl or nonyl ester groups at positions 3 and 5 was performed. Treatment of the corresponding 2',6'-dimethyl-1',4'-dihydro-[3,4'-bipyridine]-3',5'-dicarboxylates with Selectfluor® followed by quaternization of pyridine moiety in the obtained dialkyl 2,4-diacetyl-2,4-difluoro-3-(pyridin-3-yl)pentanedioates with methyl iodide gave the desired 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodides. This type of compound would be useful as synthetic lipids for further development of the delivery systems. The obtained target compounds were fully characterized by 1H NMR, 19F NMR, 13C NMR, HRMS, IR and UV data. The estimation of self-assembling properties and characterization of the nanoparticles obtained by ethanol solution injection in an aqueous media were performed by dynamic light scattering (DLS) measurements. DLS measurement data showed that 3-(3,5-difluoro-3,5-bis((nonyloxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodide created liposomes with the average diameter of 300–400 nm and polydispersity index (PDI) value around 0.30–0.40, while 3-(3,5-difluoro-3,5-bis((ethyloxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodide formed a heterogeneous sample with PDI value 1, which was not prospective for delivery system development.

Keywords: 2,4-diacetyl-2,4-difluoro-3-pyridinylpentanedioates; Selectfluor®; pyridinium; DLS; nanoparticles; self-assembling properties; synthetic lipids

1. Introduction

N-Heterocyclic compounds represent a large class of organic molecules, where many representatives possess various biological activities and are widely applied in medicine. Pyridine and structurally related molecules—dihydropyridine and pyridinium derivatives—are suggested as prevalent structural units for pharmaceutical targets [1]. According to the US Food and Drug Administration (FDA) database, a pyridine and dihydropyridine system containing drugs reaches almost 18% of the N-heterocyclic drugs approved by the agency in the major therapeutic areas—infectious diseases, inflammation, the nervous system and oncology [2]. Additionally, structurally diverse pyridinium salts are quite common structures in various pharmaceuticals and many natural compounds. Pyridinium salts are usable in a wide range of research topics. Pyridinium ionic liquids and pyridinium ylides are used in synthetic chemistry and in material science and biological issues related to gene delivery, antimicrobial, anticancer and antimalarial activities [3]. Different SAINT pyridinium salts with alkyl chain variations at the quaternized pyridine N-atom or as substituents at the pyridinium cycle were proposed as active gene delivery agents by several
research groups [4–6]. Additionally, gemini dioleylbispyridinium-based amphiphiles were elaborated for nucleic acid transfection [7].

Pyridinium salts based on 1,4-dihydropyridine (1,4-DHP) core possessed self-assembling properties, formed liposomes, and some of them were found to be active in DNA delivery [8–10]. These liposomes filled with magnetic iron oxide nanoparticles formed magnetoliposomes [11]. Magnetic nanoparticles functionalized by pyridinium moieties containing 1,4-DHP demonstrated bactericidal and immunomodulatory properties [12]. It was also found that amphiphilic 1,4-DHP, depending on the structure, possessed selective cytotoxicity—significant cytotoxicity toward cancer cell lines HT-1080 and MH-22A with still very low cytotoxicity in noncancerous NIH3T3 cells [13]. It was recently demonstrated that 4-(N-alkylpyridinium)-1,4-DHP showed toxicity in Gram-positive and Gram-negative bacteria species and eukaryotic microorganisms [14], and they also demonstrated calcium channel blocking and antioxidant activities [15]. It was shown that 4-(N-dodecylpyridinium)-1,4-dihydropyridine crossed the blood–brain barrier and blocked neuronal and vascular calcium channels [16].

The interest in fluorinated surfactants has increased due to their chemical and biological inertness and their hydrophobic and, at the same time, lipophilic character. Fluorous-containing amphiphiles are important for the formation of uniform nanoparticles, avoiding protein denaturation, efficient endocytosis and maintaining low cytotoxicity [17,18]. Several new fluorinated surfactants on the base of pyridinium salts were recently synthesized and studied as drug carriers and gene delivery systems with very promising results [19–22].

Herein, we report the synthesis and full characterization of new original synthetic lipid-like compounds: 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodide (4a) and 3-(3,5-difluoro-3,5-bis((nonyloxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodide (4b). The evaluation of the self-assembling properties of target iodoses 4 and characterization of formed nanoparticles were performed by DLS measurements in an aqueous solution.

2. Results and Discussion

Taking into account the fact that the introduction of fluorine atoms in the synthetic cationic lipid structure may lead to the formation of the original delivery systems with more pronounced properties, the synthesis of 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodies 4 was performed.

The desired target products—3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodies 4—due to cationic moiety and lipophilic substituents would be useful as synthetic lipids for further development of delivery systems.

3-(3,5-Difluoro-3,5-bis((ethoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodie (4a) and 3-(3,5-difluoro-3,5-bis((nonyloxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodie (4b) were synthesized via a three-step procedure. The synthetic procedure and the structures of all compounds were depicted in Scheme 1.

![Scheme 1. Synthesis of 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodos 4a,b.](image)

Firstly, the parent 2',6'-dimethyl-1',4'-dihydro-[3,4'-bipyridine]-3',5'-dicarboxylates 1a,b were obtained in good yields by three-component Hantzsch-type one-pot cyclocondensation reaction of the corresponding acetoacetate, 3-pyridinecarbaldehyde and ammonia.
solution in ethanol under reflux for 8 h according to the previously described procedures [23,24]. The next step—electrophilic fluorination of 1,4-DHPs 1 with Selectfluor® (2)—was performed following a procedure elaborated by our research group [25,26] and resulted in the formation of fluorne-containing dialkyl 3-(pyridin-3-yl)pentanedioates 3a and 3b with yields of 98 and 94%, respectively. The electrophilic fluorination of aromatic heterocyclic systems has been less studied than the fluorination of arenes. However, a number of heterocycles, including 1,2-dihydropyridines [27], quinolines [28] and indoles [29,30] were modified either by direct fluorination or by fluordecarboxylation using mainly Selectfluor® or N-fluorobenzenesulfonyl chloride. The last step—treatment of dialkyl 2,4-diacetyl-2,4-difluoro-3-(pyridin-3-yl)pentanedioates 3 with an excess of methyl iodide—led to quaternization of the pyridine moiety and formation of target compounds—3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodides 4 with 56 and 43% yields, respectively. Quaternization reactions of 4-pyridyl-1,4-dihydropyridines were usually carried out in acetone or in an acetone–chloroform mixture if the starting substance was insoluble in acetone [23] or in methyl ethyl ketone (MEK), which decreased the reaction time and increased the yield of product [24]. In this work, quaternization reaction was performed in MEK, and the average yields of the product can be explained by steric hindrance.

The structures of compounds 3a,b and 4a,b were established and confirmed on the basis of one-dimensional 1H, 19F, 13C NMR spectral data (Supplementary Materials).

In the 19F NMR spectra of compounds 3a,b and 4a,b, a signal of the fluorine atom appeared as a doublet in the range of $-166.1$ ppm to $-166.5$ ppm with the constants around $3J_{F-H} = 29$ Hz for compounds 3a,b and in the range of $-163.2$ ppm to $-163.3$ ppm with the constants around $3J_{F-H} = 25$ Hz for compounds 4a,b. The corresponding constants were also observed in the 1H NMR spectra for the proton attached to the carbon between the two CF groups, which appeared as a triplet in the range of 4.92–4.93 ppm for compounds 3a,b and at 5.10–5.11 ppm for 4a,b.

CF carbon atoms appeared characteristically as doublet multiplets in the 13C NMR spectra at 99.2–101.4 ppm for compounds 3a,b and at 97.7–99.9 ppm for 4a,b with the constants around $1J_{C-F} = 213$ Hz and $1J_{C-F} = 210$ Hz, respectively.

The self-assembling properties of synthetic lipid-like compounds, including cationic moieties containing 1,4-DHPs, are their characteristic feature. The hydrodynamic average diameters ($Z_{av}$) and polydispersity index (PDI) and stability of nanoparticles formed by 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodides 4a,b in aqueous medium were determined by the DLS method. The results are summarized in Table 1. The DLS measurements were performed for a freshly prepared sample and after storage for 1 and 5 days at room temperature.

Table 1. Values of polydispersity index (PDI) and $Z_{av}$ diameter of nanoparticles formed by 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodides 4a,b obtained by DLS measurements. The PDI value describes polydispersity of the sample; the $Z_{av}$ diameter represents the average hydrodynamic diameter of all nanoparticles in the sample.

| Comp. | PDI | $Z_{av}$, D_{H}, nm |
|-------|-----|------------------|
|       | Fresh * | 1 Day ** | 5 Days *** | Fresh * | 1 Day ** | 5 Days *** |
| 4a    | 1.00 ± 0.01 | - | - | 736 ± 84 | - | - |
| 4b    | 0.31 ± 0.05 | 0.42 ± 0.04 | 0.40 ± 0.06 | 371 ± 49 | 335 ± 66 | 427 ± 53 |

* Freshly prepared sample; ** After storage for 1 day at r. t.; *** After storage for 5 days at r. t.

It was demonstrated that 3-(3,5-difluoro-3,5-bis((nonyloxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodide (4b) formed nanoparticles with the average diameter around 370 nm for a freshly prepared sample; after 5 days of storage, the average diameter of the nanoparticles increased to about 430 nm. The values of PDI were 0.30 for a freshly prepared sample and around 0.40 for the samples after the storage. These values confirmed
that the sample can be considered as homogenous. It is suggested that for lipid-based formulations in drug delivery applications, PDI values of 0.3 and below are considered as acceptable and indicate homogenous populations of particles [31,32]. A sample of 3-(3,5-difluoro-3,5-bis((ethyloxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodide (4a) formed particles with a PDI value of 1, which demonstrated the heterogeneity of the sample and confirmed that the compound was not prospective for delivery system development. The evaluation of the sample formed by compound 4a will not be tested and discussed further. Previously, we obtained similar data for nanoparticles formed by 4-(N-alkylpyridinium)-1,4-DHP derivatives; compounds containing short alkyl chains at quaternized pyridinium moiety and/or 3,5-ester moieties of the 1,4-DHP cycle were not prospective as delivery systems [14]. Additionally, the results regarding membranotropic effects of 4-(N-alkylpyridinium)-1,4-DHP derivatives demonstrated the influence of the length of alkyl chain at quaternized pyridinium moiety upon the incorporation of 4-(N-alkylpyridinium)-1,4-DHP derivatives in the liposomal membranes and the influence on bilayer fluidity [33]. We confirmed the conclusion that variation in the N-alkylpyridinium chain length also impacted the self-assembling properties of the molecules for 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodides having ethyl (4a) or nonyl (4b) ester groups.

3. Materials and Methods

All reagents were purchased from Acros Organics (Geel, Belgium), Sigma-Aldrich/Merck KGaA (Darmstadt, Germany) or Alfa Aesar (Lancashire, UK) and used without further purification. TLC was performed on silica gel 60 F254 aluminum sheets 20 cm × 20 cm (Merck KGaA, Darmstadt, Germany). The melting points were recorded on an OptiMelt digital melting point apparatus (Stanford Research Systems, Sunnyvale, CA, USA) and were uncorrected. 1H, 19F and 13C NMR spectra were recorded on a Bruker Avance Neo 400 MHz (Bruker Biospin Gmbh, Rheinstetten, Germany). Chemical shifts of the hydrogen, carbon and fluorine atoms are presented in parts per million (ppm) and referred to the residual signals of the undeuterated CDCl3 (δ: 7.26) solvent for the 1H NMR spectra and CDCl3 (δ: 77.16) solvent for the 13C NMR, respectively. For the 19F-NMR experiments, indirect referencing (Bruker standard referencing) was used. The coupling constants J were reported in hertz (Hz). High-resolution mass spectra (HRMS) were determined on an Acquity UPLC H-Class system (Waters, Milford, MA, USA) connected to a Waters Synapt GII Q-ToF operating in the ESI positive or negative ion mode on a Waters Acquity UPLC® BEH C18 column (1.7 μm, 2.1 mm × 50 mm, using gradient elution with acetonitrile (0.1% formic acid) in water (0.1% formic acid)). Infrared spectra were recorded with a Prestige-21 FTIR spectrometer (Shimadzu, Kyoto, Japan). UV spectra were recorded on a UV-Vis Spectrophotometer (501 UV-Vis CamSpec Spectrophotometer; Spectronic CamSpec Ltd., Leeds, UK). The DLS measurements of the nanoparticles in aqueous solution were carried out on a Zetasizer Nano ZSP (Malvern Panalytical Ltd., Malvern, UK) instrument with Malvern Instruments Ltd. Software 8.01.4906.

3.1. General Procedure for the Synthesis of Dialkyl 2,4-Diacetyl-2,4-difluoro-3-(pyridin-3-yl)pentanedioates 3a,b

To a stirred solution of 4-pyridyl-1,4-dihydropyridines 1a,b [23,24] (1.5 mmol) in acetonitrile (15 mL), water (2 mL) was added, after which Selectfluor® (2, 1.34 g, 3.8 mmol) was added in portions at room temperature. After being stirred at reflux for 1 h, the solvents were evaporated in vacuo. Then, the remaining residue was diluted with dry diethyl ether (30 mL), and the precipitate was filtered off. The filtrate was concentrated in vacuo. Compound 3a was obtained as solid; compound 3b was obtained as oil. Compound 3a was recrystallized from EtOH. Compounds 3a,b were obtained in 94–98% yields.
3.2. Diethyl 2,4-Diacetyl-2,4-difluoro-3-(pyridin-3-yl)pentanedioate (3a)

Yield: 98%. Pale yellow solid; m.p. 84–85 °C (EtOH). *H NMR (400 MHz, CDCl3) δ: 8.60 (s, 1H, Py), 8.51 (dd, 3JH-H = 4.8 Hz, 4JH-H = 1.5 Hz, 1H, Py). 7.71 (d, 3JH-H = 7.6 Hz, 1H, Py), 7.22 (dd, 3JH-H = 8.0 Hz, 3JH-H = 4.8 Hz, 1H, Py), 4.92 (t, 3JH-H = 29.3 Hz, 1H, CH3), 4.33–4.19 (m, 4H, 2 × OCH2CH3). 2.02 (m, 6H, 2 × COCH3). 1.31 (t, 3JH-H = 7.2 Hz, 6H, 2 × OCH2CH3) ppm. 19F NMR (376 MHz, CDCl3) δ: −166.5 (3JF-H = 29.3 Hz, 2F) ppm.

13C NMR (101 MHz, CDCl3) δ: 200.5 (dd, 3JCF = 28.7 Hz, 4JCF = 12.8 Hz, 2 × C(OCH3)) ppm. 15N NMR (101 MHz, CDCl3) δ: 164.6 (dd, 3JCF = 25.5 Hz, 4JCF = 15.6 Hz, 2 × C(O)OC2H5), 152.2 (s, Py), 149.8 (s, Py), 139.2 (s, Py), 128.3 (s, Py), 123.3 (s, Py), 102.3 (dd, 3JCF = 213.0 Hz, 3JCF = 3.4 Hz, 2 × CF), 63.6 (s, 2 × OCH2CH3), 49.9 (t, 3JCF = 18.3 Hz, CH3), 26.4 (s, 2 × CH3), 13.9 (s, 2 × OCH2CH3) ppm. IR v max (film) 2967 (w), 2941 (m), 1757 (s), 1737 (s), 1570 (s) cm−1. UV-Vis λ max (EtOH): 210 (log ε 4.70), 260 (3.53) nm. HRMS TOF ESI+ of [C18H21F2NO6 + H]+ (m/z) 386.1420; calcld: 386.1415.

3.3. Dinonyl 2,4-Diacetyl-2,4-difluoro-3-(pyridin-3-yl)pentanedioate (3b)

Yield: 94%. Pale brownish oil. *H NMR (400 MHz, CDCl3) δ: 8.60 (s, 1H, Py), 8.51 (dd, 3JH-H = 4.8 Hz, 4JH-H = 1.7 Hz, 1H, Py), 7.70 (d, 3JH-H = 8.0 Hz, 1H, Py), 7.21 (d, 3JH-H = 8.0 Hz, 4JH-H = 4.8 Hz, 1H, Py), 4.93 (t, 3JH-H = 29.1 Hz, 1H, CH3), 4.23–4.11 (m, 4H, 2 × CH2CH2CH2CH2CH3), 2.03 (m, 6H, 2 × COCH3). 1.70–1.63 (m, 4H, 2 × OCH2CH2CH2CH2CH3). 1.30–1.26 (m, 24H, 2 × CH2CH2CH2CH2CH3). 0.87 (m, 6H, 2 × OCH2CH2CH2CH2CH3) ppm. 19F NMR (376 MHz, CDCl3) δ: −166.3 (3JF-H = 29.1 Hz, 2F) ppm. 13C NMR (101 MHz, CDCl3) δ: 200.5 (dd, 3JCF = 28.7 Hz, 4JCF = 12.2 Hz, 2 × C(OCH3)H19), 152.2 (s, Py), 149.8 (s, Py), 139.2 (s, Py), 128.4 (s, Py), 123.2 (s, Py), 100.3 (dd, 3JCF = 212.9 Hz, 3JCF = 3.5 Hz, 2 × CF), 67.6 (s, 2 × OCH2CH2CH2CH2CH3), 49.9 (t, 3JCF = 18.2 Hz, CH3), 32.0 (s, 2 × CH2), 29.6 (s, 2 × CH2), 29.3 (s, 2 × CH2), 29.2 (s, 2 × CH2), 28.3 (s, 2 × CH2), 26.4 (s, 2 × CH3), 25.8 (s, 2 × CH2), 22.8 (s, 2 × CH3), 14.3 (s, 2 × CH3) ppm. IR v max (film) 3181 (w), 2955 (m), 2928 (s), 2856 (m), 1761 (s), 1730 (s), 1576 (s) cm−1. UV-Vis λ max (EtOH): 210 (log ε 4.94), 260 (4.48) nm. HRMS TOF ESI+ of [C32H49F2NO6 + H]+ (m/z) 582.3621; calcld: 582.3606.

3.4. General Procedure for the Synthesis of 3-(3,5-Difluoro-3,5-bis(alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium Iodide 4a,b

To a stirred solution of 2,4-diacetyl-2,4-difluoro-3-(pyridin-3-yl)pentanedioates 3a,b (1.0 mmol) in methyl ethyl ketone (MEK), methyl iodide (5.0 mmol) was added in portions over 3 h, after which the reaction mixture was refluxed for 24 h. After overnight cooling of the reaction mixture to + 4 °C, the formed precipitates were filtered off (for compound 4a). In the case of product 4b, the solvent was evaporated, after which the residue was treated with diethyl ether, and the formed precipitates were filtered off. The obtained products were recrystallized from acetonitrile.

3.5. 3-(3,5-Difluoro-3,5-bis(ethoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium Iodide (4a)

Yield: 56%. Yellow solid; m.p. 153–154 °C (acetone). *H NMR (400 MHz, CDCl3) δ: 9.65 (d, 3JH-H = 6.0 Hz, 1H, Py), 8.65 (m, 1H, Py). 8.38 (d, 3JH-H = 8.1 Hz, 1H, Py), 8.15 (dd, 3JH-H = 8.1 Hz, 3JH-H = 6.0 Hz, 1H, Py). 5.11 (t, 3JH-H = 24.7 Hz, 1H, CH3), 4.70 (s, 3H, CH3), 4.34–4.20 (m, 4H, 2 × OCH2CH3). 2.27 (m, 6H, 2 × C(O)CH3). 1.30 (m, 6H, 2 × OCH2CH3) ppm. 19F NMR (376 MHz, CDCl3) δ: −163.2 (d, 3JF-H = 24.7 Hz, 2F) ppm. 13C NMR (101 MHz, CDCl3) δ: 200.7–200.2 (m, 2 × C(O)CH3), 163.9–163.5 (m, 2 × C(O)OCH3CH3), 146.3 (m, Py), 133.9 (s, Py), 127.9 (s, Py), 98.8 (dd, 3JCF = 209.6 Hz, 3JCF = 1.6 Hz, 2 × CF), 64.2 (s, 2 × OCH2CH3), 50.3 (s, CH3), 49.2 (t, 3JCF = 19.2 Hz, CH3), 27.0 (s, 2 × C(O)CH3), 13.9 (s, 2 × OCH2CH3) ppm. IR v max (film) 3452 (b, w), 2995 (b, w), 2939 (b, w), 2975 (m), 1756 (s), 1730 (m), 1636 (w), 1511 (w) cm−1. UV-Vis λ max (EtOH): 214 (log ε 5.40), 265 (4.85) nm. HRMS TOF ESI+ of [C10H12F2NO6]+ (m/z) 400.1579; calcld: 400.1572.
3.6. 3-(3,5-Difluoro-3,5-bis((nonyloxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodide (4b)

Yield: 43%. Pale yellow solid; m.p. 129–130 °C (acetone). $^1$H NMR (400 MHz, CDCl$_3$) δ: 9.66 (d, $^3$J$_{H-H}$ = 6.1 Hz, 1H, Py), 8.53 (m, 1H, Py), 8.37 (d, $^3$J$_{H-H}$ = 8.4 Hz, 1H, Py), 8.12 (dd, $^3$J$_{H-H}$ = 8.4 Hz, $^5$J$_{H-H}$ = 6.1 Hz, 1H, Py), 5.10 (t, $^3$J$_{H-F}$ = 25.0 Hz, 1H, CH), 4.68 (s, 3H, CH$_3$), 4.26–4.13 (m, 4H, 2 × OCH$_2$CH$_2$(CH$_2$)$_6$CH$_3$), 2.27 (m, 6H, 2 × COCH$_3$), 1.66 (m, 4H, 2 × OCH$_2$CH$_2$(CH$_2$)$_6$CH$_3$), 1.29–1.25 (m, 24H, 2 × OCH$_2$CH$_2$(CH$_2$)$_6$CH$_3$), 0.87 (m, 6H, 2 × OCH$_2$CH$_2$(CH$_2$)$_6$CH$_3$) ppm. $^{19}$F NMR (376 MHz, CDCl$_3$) δ: −163.3 (d, $^3$J$_{F-H}$ = 25.0 Hz, 1F) ppm. $^{13}$C NMR (101 MHz, CDCl$_3$) δ: 208.0–200.4 (m, 2 × C(OC(CH$_3$)$_3$)), 164.1–163.2 (m, 2 × C(O)OCH$_2$CH$_2$(CH$_2$)$_6$CH$_3$), 146.4 (m, Py), 134.1 (s, Py), 128.0 (s, Py), 98.9 (dm, $^1$J$_{C-F}$ = 210.1 Hz, 2 × CF), 68.3 (s, 2 × OCH$_2$CH$_2$(CH$_2$)$_6$CH$_3$), 50.2 (s, CH$_3$), 49.3 (t, $^1$J$_{C-F}$ = 19.2 Hz, CH), 31.9 (s, 2 × CH$_2$), 29.5 (s, 2 × CH$_2$), 29.3 (s, 2 × CH$_2$), 29.1 (s, 2 × CH$_2$), 28.2 (s, 2 × CH$_2$), 26.8 (s, 2 × C(OC(CH$_3$)$_3$), 22.7 (s, 2 × CH$_2$), 14.2 (s, 2 × OCH$_2$CH$_2$(CH$_2$)$_6$CH$_3$) ppm. IR ν max (film) 3470 (b, w), 3033 (w), 2955 (m), 2924 (m), 2000 (m), 1770 (m), 1500 (w), 1390 (w) cm$^{-1}$. UV-Vis λ max (EtOH): 214 (log ε 5.43), 265 (4.94) nm. HRMS TOF ESI$^+$ of [C$_{33}$H$_{52}$F$_2$NO$_6$]+ (m/z) 596.3773; calcd: 596.3763.

3.7. Self-Assembling Properties by Dynamic Light Scattering Measurements

Samples of 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodides 4a,b for dynamic light scattering (DLS) studies were prepared utilizing the ethanol injection technique. A solution of compound 4a or compound 4b (300 µL, 1 mM in EtOH 96%) was injected into 2.70 mL deionized water with maximum stirring (IKA Vortex 2 (IKA, Staufen, Germany)) to give a final concentration of the compound—100 µM. The sample was sonicated for 60 min at 50 °C using a bath-type sonicator (Cole Parmer Ultrasonic Cleaner 8891CPX (Vernon Hills, IL, USA)).

The DLS measurements of the nanoparticles in aqueous solution were carried out on a Zetasizer Nano ZSP (Malvern Panalytical Ltd., Malvern, UK) instrument with Malvern Instruments Ltd. Software 8.01.4906, using the following specifications: medium—water; refractive index—1.33; viscosity—0.8872 cP; temperature—25 °C; dielectric constant—78.5; nanoparticles—liposomes; refractive index of materials—1.60; detection angle—173°; wavelength—633 nm. Data were analyzed using the multimodal number distribution software that was included with the instrument. The measurements were performed in triplicate in order to check their reproducibility. The measurements were performed in triplicate in order to check their reproducibility. Example of DLS data for freshly prepared nanoparticles of 4b see in the Supplementary Materials.

3.8. Statistical Analysis

Results are expressed as mean standard deviation (SD). All experiments were performed in triplicate.

4. Conclusions

Synthesis of the ethyl or nonyl ester containing 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodides 4a and 4b was performed after treatment of the corresponding 2′,6′-dimethyl-1′,4′-dihydro-[3′,4′-bipyridine]-3′,5′-dicarboxylates with Selectfluor®, which gave dialkyl 2,4-diacetyl-2,4-difluoro-3-(pyridin-3-yl) pentanedioates. Quaternization of pyridine moiety of dialkyl 2,4-diacetyl-2,4-difluoro-3-(pyridin-3-yl) pentanedioates with methyl iodide resulted in target compounds. The compounds were characterized by fully characterized by $^1$H NMR, $^{19}$F NMR, $^{13}$C NMR, HRMS, IR and UV data. DLS measurements demonstrated that 3-(3,5-difluoro-3,5-bis((nonyloxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodide (4b) formed nanoparticles with the average diameter around 370/430 nm and PDI values 0.3/0.4 for a freshly prepared sample and sample after 5 days of storage, respectively. Meanwhile, a sample of 3-(3,5-difluoro-3,5-bis((ethyloxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methyl-pyridin-1-ium iodide (4a) formed particles with a PDI value of 1, which indicated the heterogeneity of the
sample. It was demonstrated that variation in the N-alkylpyridinium chain length also impacted the self-assembling properties of the molecules in the case of 3-(3,5-difluoro-3,5-bis((alkoxy)carbonyl)-2,6-dioxoheptan-4-yl)-1-methylpyridin-1-ium iodides.

Supplementary Materials: The following are available online. File S1. 1H NMR, 19F NMR, 13C NMR and HRMS spectra of compounds 3a,b and 4a,b, example of DLS data for freshly prepared nanoparticles of 4b.

Author Contributions: Conceptualization was conducted by N.P. and A.P.; methodology and experimental works were conducted by N.P., M.R., M.P., K.P., D.L., A.S. and A.P.; data analysis, writing and editing of the paper were conducted by A.S., M.R., N.P. and A.P.; project administration and supervision were conducted by N.P., A.S. and A.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by EuroNanoMed3 project NANO4GLIO No ES RTD/2020/9 and PostDocLatvia Project No 1.1.1.2/VIAA/3/19/587 (K.Pajuste).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in this article.

Acknowledgments: We are indebted to Marina Petrova for recording the NMR and IR spectra, and to Solveiga Grinberga for the mass spectral analyses.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hamada, Y. Role of Pyridines in Medicinal Chemistry and Design of BACE1 Inhibitors Possessing a Pyridine Scaffold. In Pyridine; Pratima, P., Ed.; IntechOpen: London, UK, 2018; ISBN 978-1-78923-423-7.
2. Ling, Y.; Hao, Z.Y.; Liang, D.; Zhang, C.L.; Liu, Y.F.; Wang, Y. The expanding role of pyridine and dihydropyridine scaffolds in drug design. Drug Des. Deliv. Ther. 2021, 15, 4289–4338. [CrossRef] [PubMed]
3. Sowmiah, S.; Esperança, J.M.S.S.; Rebelo, L.P.N.; Afonso, C.A.M. Pyridinium salts: From synthesis to reactivity and applications. Org. Chem. Front. 2018, 5, 453–493. [CrossRef]
4. Ilies, M.A.; Satyal, U.; Sharma, V.D. Synthetic delivery systems for DNA, siRNA, and mRNA based on pyridinium amphiphiles. In Proceedings of the ACS Symposium Series; American Chemical Society: Washington, DC, USA, 2017; Volume 1271, pp. 1–34.
5. Ilies, M.A.; Seitz, W.A.; Johnson, B.H.; Ezell, E.L.; Miller, A.L.; Thompson, E.B.; Balaban, A.T. Lipophilic pyrylum salts in the synthesis of efficient pyridinium-based cationic lipids, gemini surfactants, and lipophilic oligomers for gene delivery. J. Med. Chem. 2006, 49, 3872–3887. [CrossRef]
6. Satyal, U.; Draghici, B.; Dragic, L.L.; Zhang, Q.; Norris, K.W.; Madesh, M.; Brailoiu, E.; Ilies, M.A. Interfacially Engineered Pyridinium Pseudogemini Surfactants as Versatile and Efficient Supramolecular Delivery Systems for DNA, siRNA, and mRNA. ACS Appl. Mater. Interfaces 2017, 9, 29481–29495. [CrossRef] [PubMed]
7. Aubets, E.; Grier, R.; Felix, A.J.; Rigol, G.; Sikorski, C.; Limón, D.; Mastrorosa, C.; Busquets, M.A.; Pérez-García, L.; Noé, V.; et al. Synthesis and validation of DOPY: A new gemini dioleylbisperpyridinium based amphiphile for nucleic acid transfection. Eur. J. Pharm. Biopharm. 2011, 76, 279–292. [CrossRef] [PubMed]
8. Hyvönen, Z.; Plotniece, A.; Reine, I.; Chekavichus, B.; Duburs, G.; Urtti, A. Novel cationic amphiphilic 1,4-dihydropyridine derivatives for DNA delivery. Biochim. Biophys. Acta Biomembr. 2000, 1509, 451–466. [CrossRef]
9. Pajuste, K.; Hyvonen, Z.; Petrichenko, O.; Kaldre, D.; Rucins, M.; Cekavicus, B.; Ose, V.; Skrivele, B.; Gosteva, M.; Morin-Picardat, E.; et al. Gene delivery agents possessing antiradical activity: Self-assembling cationic amphiphilic 1,4-dihydropyridine derivatives. New J. Chem. 2013, 37, 3062–3075. [CrossRef]
10. Petrichenko, O.; Rucins, M.; Bezane, A.; Timofieva, I.; Sobolev, A.; Cekavicus, B.; Pajuste, K.; Plotniece, M.; Gosteva, M.; Kozlovskova, T.; et al. Studies of the physicochemical and structural properties of self-assembling cationic pyridine derivatives as gene delivery agents. Chem. Phys. Lipids 2015, 191, 25–37. [CrossRef]
11. Petrichenko, O.; Plotniece, A.; Pajuste, K.; Rucins, M.; Dimitrijevs, P.; Sobolev, A.; Sprugis, E.; Cēbers, A. Evaluation of physicochemical properties of amphiphilic 1,4-dihydropyridines and preparation of magnetoliposomes. Nanomaterials 2021, 11, 1–17. [CrossRef]
12. Niemtirowicz-Laskowska, K.; Gluszek, K.; Piktel, E.; Pajuste, K.; Durnaš, B.; Król, G.; Wilczewska, A.Z.; Janmey, P.A.; Plotniece, A.; Bucki, R. Bactericidal and immunomodulatory properties of magnetic nanoparticles functionalized by 1,4-dihydropyridines. Int. J. Nanomed. 2018, 13, 3411–3424. [CrossRef]
13. Rucins, M.; Smits, R.; Sipola, A.; Vigante, B.; Domracheva, I.; Turovska, B.; Muhamedjev, R.; Pajuste, K.; Plotniece, M.; Sobolev, A.; et al. Pleiotropic Properties of Amphiphilic Dihydropyridines, Dihydropyridones, and Aminovinylcarbonyl Compounds. Oxid. Med. Cell. Longev. 2020, 2020. [CrossRef] [PubMed]

14. Rucins, M.; Dimitrijevs, P.; Pajuste, K.K.; Petrichenko, O.; Jackevica, L.; Gulbe, A.; Kibilda, S.; Smits, K.; Plotniece, M.; Tirzite, D.; et al. Contribution of Molecular Structure to Self-Assembling and Biological Properties of Bifunctional Lipid-Like 4-(N-Alkylpyridinium)-1,4-Dihydropyridines. Pharmaceuticals 2019, 11, 115. [CrossRef] [PubMed]

15. Rucins, M.; Kaldre, D.; Pajuste, K.; Fernandes, M.A.S.; Vicente, J.A.F.; Klimavicius, L.; Jaschenko, E.; Kanep-Lapsa, I.; Shestakova, I.; Plotniece, M.; et al. Synthesis and studies of calcium channel blocking and antioxidant activities of novel 4-pyridinium- and/or N-propargyl substituted 1,4-dihydropyridine derivatives. Comptes Rendus Chim. 2014, 17, 69–80. [CrossRef]

16. Jansone, B.; Kadish, I.; Van Groen, T.; Beinare, U.; Moore, D.R.; Plotniece, A.; Pajuste, K.; Klusa, V. A novel 1,4-dihydropyridine derivative improves spatial learning and memory and modifies brain protein expression in wild type and transgenic APPSwe/192P103M Mice. PLoS ONE 2015, 10, e0127686. [CrossRef] [PubMed]

17. Boussif, O.; Gaucherhon, J.; Boulanger, C.; Santaella, C.; Kolbe, H.V.J.; Vierling, P. Enhanced in vitro and in vivo cationic lipid-mediated gene delivery with a fluorinated glycerolphosphoethanolamine helper lipid. J. Gene Med. 2001, 3, 109–114. [CrossRef]

18. Zhang, Z.; Shen, W.; Ling, J.; Yan, Y.; Hu, J.; Cheng, Y. The fluorination effect of fluoroamphiphiles in cytosolic protein delivery. Nat. Commun. 2018, 9, 1–8. [CrossRef]

19. Boulanger, C.; Di Giorgio, C.; Gaucheron, J.; Vierling, P. Transfection with Fluorinated Lipoplexes Based on New Fluorinated Cationic Lipids and in the Presence of a Bile Salt Surfactant. Bioconjug. Chem. 2004, 15, 901–908. [CrossRef]

20. Fisicaro, E.; Compari, C.; Bacciottini, F.; Contardi, L.; Pongiluppi, E.; Barbero, N.; Viscardi, G.; Quagliotto, P.; Donofrio, G.; Krafft, M.P. Nonviral gene-delivery by highly fluorinated gemini bispyridinium surfactant-based DNA nanoparticles. J. Colloid Interface Sci. 2017, 487, 182–191. [CrossRef]

21. Massa, M.; Rivara, M.; Donofrio, G.; Cristofolini, L.; Peracchia, E.; Compari, C.; Bacciottini, F.; Orsi, D.; Franceschi, V.; Fisicaro, E. Gene-Delivery Ability of New Hydrogenated and Partially Fluorinated Gemini Bispyridinium Surfactants with Six Methylene Spacers. Int. J. Mol. Sci. 2022, 23, 3062. [CrossRef]

22. Liu, J.; Li, S.; Liu, L.; Zhu, Z. A fluorous biphasic drug delivery system triggered by low frequency ultrasound: Controlled release from perfluorous discoidal porous silicon particles. Nanoscale Adv. 2020, 2, 3561–3569. [CrossRef]

23. Makarova, N.V.; Koronova, Z.V.; Plotnietse, A.V.; Tirzite, D.Y.; Tirzit, G.D.; Duburs, G.Y. Synthesis of 1,4-dihydropyridines having an N-alkylpyridinium substituent at the 4-position and their affinity towards liposomal membranes. Chem. Heterocycl. Compd. 1995, 31, 969–973. [CrossRef]

24. Pajuste, K.; Gosteva, M.; Kaldre, D.; Plotniece, M.; Cekavicus, B.; Sobolev, A.; Priksane, A.; Tirzitis, G.; Duburs, G.; Plotniece, A. Effect of the solvent nature on the course of quaternization of 3,5-diethoxy carbonyl-2,6-dimethyl-1-(3-pyridyl)-1,4-dihydropyridine. Chem. Heterocycl. Compd. 2011, 47. [CrossRef]

25. Pikun, N.V.; Kolesnyk, N.P.; Rusanov, E.B.; Plotniece, A.; Rucins, M.; Sobolev, A.; Shermolovich, Y.G. Synthesis of fluorinated 2,6-heptanones and 2-oxa-6-azabicyclo[2.2.2]octanes from 1,4-dihydropyridines. Tetrahedron 2018, 74, 2884–2890. [CrossRef]

26. Pikun, N.V.; Kolesnyk, N.P.; Rusanov, E.B.; Plotniece, A.; Sobolev, A.; Domracheva, I.; Shermolovich, Y.G. Contrasting reactivity of fluorinated 2,6-heptanones towards amines and ammonia, leading to cyclohexanediones or 2-oxa-6-azabicyclo[2.2.2]octanes and evaluation of their cytotoxicity. New J. Chem. 2019, 43, 10537–10544. [CrossRef]

27. Pikun, N.V.; Sobolev, A.; Plotniece, A.; Rucins, M.; Vigante, B.; Petrova, M.; Muhamedjev, R.; Pajuste, K.; Shermolovich, Y.G. Synthesis of Fluorinated 3,6-Dihydropyridines and 2-(Fluoromethyl)pyridines by Electrophilic Fluorination of 1,2-Dihydropyridines with Selectfluor®. Molecules 2020, 25, 3143. [CrossRef] [PubMed]

28. Gu, Q.; Vessally, E. N-Fluoroobenzensulfonimidone: A Useful and Versatile Reagent for the Direct fluorination and amination of (hetero)aromatic C–H bonds. RSC Adv. 2020, 10, 16756–16768. [CrossRef]

29. Takeuchi, Y.; Tarui, T.; Shibata, N. A novel and efficient synthesis of 3-fluorooxindoles from indoles mediated by selectfluor. Org. Lett. 2000, 2, 639–642. [CrossRef]

30. Yang, Q.; Dai, G.L.; Yang, Y.M.; Luo, Z.; Tang, Z.Y. Solvent Effects: Syntheses of 3,3-Difluorooxindoles and 3-Fluorooxindoles from Hydrazonoindolin-2-one by Selectfluor. J. Org. Chem. 2018, 83, 6762–6768. [CrossRef]

31. Putri, D.C.A.; Dwiastuti, R.; Marchaban, M.; Nugroho, A.K. Optimization of mixing temperature and sonication duration in liposome preparation. J. Pharm. Sci. Community 2017, 14, 79–85. [CrossRef]

32. Danaei, M.; Dehghankhold, M.; Ataei, S.; Hasanazadeh Davaran, F.; Javanmard, R.; Dokhani, A.; Khorasani, S.; Mozafari, M.R. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018, 10, 57. [CrossRef]

33. Tirzite, D.; Koronova, J.; Plotniece, A. Influence of some quaternized 1,4-dihydropyridine derivatives on liposomes and erythrocyte membranes. Biochem. Mol. Biol. Int. 1998, 45, 849–856. [CrossRef] [PubMed]